Table 6.
Antibody response in matched KTR cohorts.
| variable | time | KTRboost | Matched KTR (unboostered) | p-value |
|---|---|---|---|---|
| IgA-Ab Spike S1 | T2 | 1·8 (1·1–3·0) | 1·8 (0·8–3·8) | 0·766 |
| IgA-Ab Spike S1 | T3 | 2 (1·6–6) | 1·0 (0·5–2·8) | 0·019 |
| IgG-Ab Spike S1 | T2 | 13·7 (4·1–22·3) | 41·6 (6·3–61·7) | 0·022 |
| IgG-Ab Spike S1 | T3 | 290·4 (75·4–384) | 51·8 (17·2–124·6) | 0·017 |
| RBD-IgG | T2 | 8·1 (4·7–12·9) | 19·0 (16·9–28·6) | < 0·001 |
| RBD-IgG | T3 | 89·3 (28·7–98·6) | 17·8 (7·1–43·5) | 0·004 |
The KTRboost group (n = 20) is defined as a very low seroconversion group with values at T2 (eight weeks) with either IgA positivity and no IgG positivity or IgG/IgA positivity and low/negative levels of RBD-IgG antibody values stimulating the individual decision for an additional boostering between T2 and T3 (six months). Propensity scores were used to match the KTRboost group with unboostered KTR (1:1 ratio). Vaccination-related antibody titre levels were compared in both groups at seroconversion (T2) and after six months (T3).